Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations (Q54650734)

2 June 2018

title

Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

non-small-cell lung carcinoma

10 July 2024

main subject

1 reference

Ya-Chieh Hsu

1 reference

2 June 2018

author name string

Jenn-Yu Wu

1 reference

2 June 2018

Shang-Gin Wu

1 reference

2 June 2018

Chih-Hsin Yang

1 reference

2 June 2018

Yih-Leong Chang

1 reference

2 June 2018

Yeun-Chung Chang

1 reference

2 June 2018

Jin-Yuan Shih

1 reference

2 June 2018

Pan-Chyr Yang

1 reference

2 June 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20832137

10 July 2024

publication date

15 September 2010

1 reference

2 June 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0169500210003922?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

https://api.elsevier.com/content/article/PII:S0169500210003922?httpAccept=text/plain

10 July 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

10 July 2024

1 reference

2 June 2018

volume

1 reference

2 June 2018

issue

1 reference

2 June 2018

page(s)

205-212

1 reference

2 June 2018

High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy

cites work

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/J.LUNGCAN.2008.02.023

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Erlotinib in previously treated non-small-cell lung cancer

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Screening for epidermal growth factor receptor mutations in lung cancer

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

10 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.LUNGCAN.2010.08.013

10 July 2024

Identifiers

1 reference

2 June 2018

1 reference

2 June 2018